伊曲康唑注射液治疗血液恶性肿瘤继发真菌感染的近期疗效和安全性观察

目的观察伊曲康唑注射液治疗血液恶性肿瘤患者继发真菌感染的近期疗效和安全性。方法选择60例临床诊断的血液恶性肿瘤继发真菌感染患者作为研究对象,随机分为观察组和对照组,每组30例,观察组患者给予常规对症治疗加伊曲康唑注射液,对照组患者给予常规对症治疗加两性霉素B治疗,疗程14d。观察两组患者近期疗效和不良反应情况。结果观察组和对照组患者总有效率分别为80.0%和53.3%,两组比较差异有统计学意义(P<0.05)。两组患者各项不良反应差异均无统计学意义(P>0.05);对照组患者不良反应发生率(66.7%)高于观察组(43.3%),但差异无统计学意义(P>0.05)。结论相对两性霉素B,应用伊曲康唑治疗血液恶性肿瘤继发真菌感染的近期疗效更好,推荐在临床上应用。不良反应有待于进一步研究。

Observation on the short-term efficacy and safety of itraconazole injection in treatment of the hema- tologic malignancies with secondary fungal infection

Objective To observe the short-term efficacy and safety of itraconazole injection in treatment of the hematologic malignancies patients with secondary fungal infection. Methods 60 cases of patients with hematological malignancies who were diagnosed clinically as the secondary fungal infection were selected as the subjects and randomly divided into the observation group and the control group （30 ca- ses respectively）. The patients in the observation group was given routine symptomatic treatment with itra- conazole injection antifungal therapy,while the patients in the control group was given routine symptomatic treatment with amphotericin B therapy. The treatment last 14 days ; the short-term effects and adverse reaction of the patients in the two groups were observed. Results After treatment, there were significant differences in the overall efficacy between the two groups （P 〈 0. 05 ）, the total efficiency of the two groups were 80. 0% and 53.3% respectively and there was significant difference between the two groups （ P 〈 0. 05 ） ; the pa- tients in the two groups experienced adverse reactions in a certain proportion. The adverse reaction rate in the control group （66. 7% ） was higher than that ill the observation group （43.3%） ,but the difference between the two groups was not significant （P 〉 0. 05）. There were no significant differences in advex~e reactions be- tween the two groups （P 〉 0. 05）. Conclusions Compared with amphotericin B, application of itraconazole in the treatment of hematological malignancies with secondary fungal infection can approach better curative effects and can be recommended in clinical application. The adve~e reactions need further study.